Chinese COVID-19 vaccine Ad5-Ncov shows high antibody levels at Russian trial -Ifax


  • World
  • Thursday, 14 Jan 2021

FILE PHOTO: Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. China Daily via REUTERS

MOSCOW (Reuters) - Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.

Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

Chinese books draw attention at int'l book fair in Algerian capital
U.S. stocks close lower as post-election rally cools
EU Commission urges Apple to end geo-blocking
U.S. stocks close lower
1st Middle East consumer electronics expo kicks off in UAE
Feature: Music provides cultural bridge between China, Italy
Jailed Belarusian dissident Kalesnikava permitted visit from father
How will the next leader of the Church of England be picked?
Crude futures settle higher
U.S. dollar ticks up

Others Also Read